Breaking News Instant updates and real-time market news.

BIIB

Biogen

$302.05

-13.95 (-4.41%)

, ESALY

Eisai

$0.00

(0.00%)

08:48
10/25/18
10/25
08:48
10/25/18
08:48

Eisai, Biogen present data from BAN2401 study at CTAD

Eisai (ESALY) and Biogen (BIIB) announced that Eisai presented the latest data from the Phase II clinical study of BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease, at a symposium session at the Clinical Trials on Alzheimer's Disease, or CTAD, conference. Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in 856 patients with mild cognitive impairment, or MCI, due to Alzheimer's disease, or AD, or mild Alzheimer's dementia with confirmed amyloid pathology in the brain. Patients were randomized to five dose regimens, 2.5 mg/kg bi-weekly, 5 mg/kg monthly, 5 mg/kg bi-weekly, 10 mg/kg monthly and 10 mg/kg bi-weekly, or placebo. This study used a Bayesian Adaptive Randomization Design to automatically allocate newly enrolled patients into the study to treatment arms showing higher probability of efficacy based on the results of interim analyses. The 10 mg/kg monthly and 10 mg/kg bi-weekly doses were determined to have greater efficacy, and as a result, the proportion of patients allocated to those treatment arms was greater. Conventional statistical methods on predefined clinical outcomes at the 18 month final efficacy time point included Alzheimer's Disease Composite Score, or ADCOMS, Alzheimer's Disease Assessment Scale-Cognitive subscale, or ADAS-Cog, and Clinical Dementia Rating Sum of Boxes, or CDR-SB. The most current data presented at CTAD 2018 highlight topline results, originally presented by Eisai in July at the Alzheimer's Association International Conference (AAIC) 2018, as well as new data from pre-specified subgroup analyses and cerebrospinal fluid (CSF) biomarkers. From conventional statistical analysis of the topline results, the highest treatment dose demonstrated a statistically significant reduction in brain amyloid measured by positron emission tomography at 18 months. This dose also showed a statistically significant slowing of clinical decline on ADCOMS of 30 percent compared to placebo at 18 months. A group-level correlation between clearance of brain amyloid and slowing of clinical decline on ADCOMS was confirmed . A linear regression model testing the slope of change from baseline on the rate of disease progression using ADCOMS showed a significant difference over 18 months for the highest treatment dose versus placebo, suggesting a potential disease-modifying effect.

BIIB

Biogen

$302.05

-13.95 (-4.41%)

ESALY

Eisai

$0.00

(0.00%)

  • 25

    Oct

  • 25

    Oct

BIIB Biogen
$302.05

-13.95 (-4.41%)

10/24/18
LEER
10/24/18
NO CHANGE
Target $340
LEER
Market Perform
Biogen price target raised to $340 form $328 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Biogen to $340 from $328 after the company reported top and bottom line beats that were driven by strong Spinraza and Tysabri revenue and lower operating expenses. This strong operating performance is somewhat overshadowed by investors' attention to new Alzheimer's disclosures, and the somewhat disappointing pipeline developments revealed during the quarter, he contends. The analyst reiterates a Market Perform rating on the shares.
10/23/18
PIPR
10/23/18
NO CHANGE
Target $400
PIPR
Overweight
Piper a buyer of Biogen shares after 'decent' Q3 report
Piper Jaffray analyst Christopher Raymond said he would characterize Biogen's Q3 report as "a decent top- and bottom-line beat" alongside a "somewhat mixed" pipeline update. Despite some pipeline setbacks, such as BIIB074 and anti-CD40L both having recently failed, he thinks more important pipeline updates are still to come and he remains a buyer of Biogen shares, also citing the stock's "attractive" valuation. Raymond keeps a Overweight rating on the stock with a $400 price target.
10/19/18
10/19/18
DOWNGRADE
Target $341

Market Perform
Bernstein downgrades Biogen to Market Perform on low odds of 2019 outperformance
As previously reported, Bernstein analyst Aaron Gal downgraded Biogen to Market Perform from Outperform, stating that its current stock price roughly reflects the market's recognition of its execution in multiple sclerosis and odds of success in Alzheimer's. He now sees limited further news on Alzheimer's in the near-term and sees potential for downside earning revision on Spinraza and multiple sclerosis competition, Gal tells investors. He lowered his price target on Biogen shares to $341, stating that he sees the stock being less likely to outperform before the start of 2020.
10/19/18
BERN
10/19/18
DOWNGRADE
BERN
Market Perform
Biogen downgraded to Market Perform from Outperform at Bernstein
ESALY Eisai
$0.00

(0.00%)

08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
07/06/18
MSCO
07/06/18
NO CHANGE
Target $369
MSCO
Overweight
Biogen likely to be up 5%-10% on positive Alzheimer's data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the fact that Eisai (ESALY) and Biogen's (BIIB) BAN2401 trial achieved positive topline results at an 18 month landmark analysis is a "clear positive" for the perception of aducanumab and he expects Biogen's shares to be up 5% to over 10% following the news. Harrison added that he would expect full data to be reported at the CTAD meeting in October as he thinks the AAIC meeting coming up in late July is too close. He keeps an Overweight rating and $369 price target on Biogen shares.

TODAY'S FREE FLY STORIES

02:50
05/21/19
05/21
02:50
05/21/19
02:50
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

02:10
05/21/19
05/21
02:10
05/21/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

OXY

Occidental Petroleum

$53.49

0.74 (1.40%)

21:25
05/20/19
05/20
21:25
05/20/19
21:25
Downgrade
Occidental Petroleum rating change at Wells Fargo »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TIGR

UP Fintech

$5.63

-0.14 (-2.43%)

20:41
05/20/19
05/20
20:41
05/20/19
20:41
Hot Stocks
Interactive Brokers Group discloses 7.6% stake in UP Fintech »

IBGI acquired beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$52.95

-0.08 (-0.15%)

, HD

Home Depot

$190.87

-1.66 (-0.86%)

20:25
05/20/19
05/20
20:25
05/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$52.95

-0.08 (-0.15%)

HD

Home Depot

$190.87

-1.66 (-0.86%)

AZO

AutoZone

$978.78

-5.21 (-0.53%)

KSS

Kohl's

$62.95

-0.68 (-1.07%)

EV

Eaton Vance

$37.27

-0.535 (-1.42%)

JCP

J.C. Penney

$1.15

0.01 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 23

    May

  • 24

    May

  • 29

    May

  • 04

    Jun

  • 11

    Jun

JCOM

j2 Global

$86.48

-0.23 (-0.27%)

20:22
05/20/19
05/20
20:22
05/20/19
20:22
Hot Stocks
j2 Global CFO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:58
05/20/19
05/20
19:58
05/20/19
19:58
Earnings
Atento sees FY19 revenue flat to up single digits »

The company sees sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:57
05/20/19
05/20
19:57
05/20/19
19:57
Earnings
Atento reports Q1 recurring EPS (6c), consensus 10c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ITCB

Itau Corpbanca

$12.95

(0.00%)

19:38
05/20/19
05/20
19:38
05/20/19
19:38
Hot Stocks
Itau Corpbanca dissolves subsidiary Corplegal »

Itau Corpbanca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

19:36
05/20/19
05/20
19:36
05/20/19
19:36
Recommendations
Ocular Therapeutix analyst commentary at Piper Jaffray »

Ocular Therapeutix price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

YGYI

Youngevity

$6.57

0.13 (2.02%)

, QFIN

360 Finance

$16.46

0.71 (4.51%)

18:55
05/20/19
05/20
18:55
05/20/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

YGYI

Youngevity

$6.57

0.13 (2.02%)

QFIN

360 Finance

$16.46

0.71 (4.51%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

TRIP

TripAdvisor

$44.93

-0.07 (-0.16%)

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

KR

Kroger

$24.04

-0.18 (-0.74%)

SNAP

Snap

$11.19

-0.3 (-2.61%)

NDSN

Nordson

$130.42

-4.8 (-3.55%)

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

SWI

SolarWinds

$19.16

0.04 (0.21%)

MRCY

Mercury Systems

$72.85

-0.11 (-0.15%)

VNE

Veoneer

$18.89

0.02 (0.11%)

GH

Guardant Health

$78.29

2.13 (2.80%)

CVNA

Carvana

$67.17

-0.935 (-1.37%)

INSM

Insmed

$28.08

-1.08 (-3.70%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 18

    Jun

  • 23

    Jun

  • 10

    Nov

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    Jun

TOL

Toll Brothers

$37.52

-0.88 (-2.29%)

18:47
05/20/19
05/20
18:47
05/20/19
18:47
Hot Stocks
Toll Brothers acquires Sharp Residential, terms not disclosed »

Toll Brothers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

18:45
05/20/19
05/20
18:45
05/20/19
18:45
General news
Breaking General news story  »

Federal Reserve Chairman…

TTWO

Take-Two

$102.94

-3.82 (-3.58%)

18:44
05/20/19
05/20
18:44
05/20/19
18:44
Hot Stocks
Take-Two CEO: Our job is to excite customers »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

AAL

American Airlines

$30.96

-0.8 (-2.52%)

18:40
05/20/19
05/20
18:40
05/20/19
18:40
Periodicals
American Air asks court to halt alleged mechanics unions' slowdown, Reuters says »

American Airlines has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

  • 12

    Jun

  • 12

    Jun

LWAY

Lifeway Foods

$2.75

0.05 (1.85%)

18:38
05/20/19
05/20
18:38
05/20/19
18:38
Earnings
Lifeway Foods reports Q1 EPS (2c) vs. 0c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WHLR

Wheeler REIT

$2.25

0.025 (1.13%)

18:31
05/20/19
05/20
18:31
05/20/19
18:31
Hot Stocks
Wheeler REIT chairman John Sweet to resign »

Wheeler Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$101.54

0.66 (0.65%)

, TGT

Target

$72.10

1.22 (1.72%)

18:03
05/20/19
05/20
18:03
05/20/19
18:03
Periodicals
Judge says Walmart, Target, Bed Bath must face suits over cotton, Reuters says »

U.S. District Judge…

WMT

Walmart

$101.54

0.66 (0.65%)

TGT

Target

$72.10

1.22 (1.72%)

BBBY

Bed Bath & Beyond

$14.48

-0.525 (-3.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 15

    Aug

  • 13

    Nov

QFIN

360 Finance

$16.46

0.71 (4.51%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Earnings
360 Finance reports Q1 net income $117.5M, up 382% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

MRK

Merck

$78.86

0.15 (0.19%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Hot Stocks
Merck falls after Keytruda trial does not meet OS primary endpoint »

Shares of Merck have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

PRIM

Primoris

$20.26

-0.08 (-0.39%)

17:55
05/20/19
05/20
17:55
05/20/19
17:55
Hot Stocks
Primoris director sells 99.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

, LM

Legg Mason

$35.68

0.295 (0.83%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
BNY Mellon announces Ed Garden to step down from board of directors »

BNY Mellon (BK) announced…

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

LM

Legg Mason

$35.68

0.295 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DHR

Danaher

$130.33

-0.81 (-0.62%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
VP of Danaher Angela Lalor sells over $408K in company shares »

VP of Danaher Angela…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 07

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

17:43
05/20/19
05/20
17:43
05/20/19
17:43
Periodicals
Judge dismisses Trump request to block accounting subpoena, WSJ says »

U.S. District Judge Amit…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$35.68

0.295 (0.83%)

17:40
05/20/19
05/20
17:40
05/20/19
17:40
Hot Stocks
Legg Mason names Nelson Peltz, Ed Garden to board of directors »

Legg Mason announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.